Korro Bio, a clinical-stage biopharmaceutical company, announced that CEO Ram Aiyar will present at the 2026 Jefferies Global Healthcare Conference in London on November 19. The company specializes in genetic medicines using its OPERA platform, which edits RNA to develop treatments for rare and common diseases. The presentation will be webcast live and available for replay, highlighting Korro's innovative approach and upcoming developments in RNA-editing therapies.
Korro Bio's upcoming presentation at the 2026 Jefferies Global Healthcare Conference in London provides context for health sector market activity. For readers following health stocks, here is Pluang's market snapshot as of Nov 06, 2026 18:31 WIB: Among 150 priced US health-sector stocks, 47 rose and 94 fell. Notable movers include BKD at USD 10.15 with a 1-day change of -6.11% and a typical hold time of 22 days, HALO at USD 115.65 down 5.95% with a 3-day hold time, and ACAD at USD 20.21 down 4.85%, with a typical hold time of 77 days and Pluang order activity showing 12% sell and 88% buy.
Nexans has signed a subcontract to deliver a 420 km mass-impregnated 110 kV cable system for the 1 GW, 320 kV Corinth-Kos HVDC interconnection in Greece. This project, awarded to Hellenic Cables and partners, will connect the Dodecanese islands to ma...
Guggenheim analyst Howard Ma raised JFrog's price target to $125, signaling a 67.5% potential upside from its current price of $74.62. JFrog reported strong Q3 2026 results with revenue up 31% year-over-year to $179.2 million, driven by a 60% surge i...
The Indonesia data center market is projected to grow from USD 2.08 billion in 2027 to USD 4.05 billion by 2032, at a CAGR of 14.28%. Growth is fueled by expanding hyperscaler cloud infrastructure, rising digital workloads, increasing demand for colo...
Tesla and SpaceX, Elon Musk's two largest public companies, lost a combined $457 billion in market value between November 3 and 5, 2026, following Democratic wins in Congress and key Texas races. Tesla's stock dropped nearly 14%, while SpaceX fell ov...
Arch Biopartners announced a non-brokered private placement of 1,058,823 shares at $0.85 each, raising $900,000 CAD. The funds will support onboarding U.S. clinical sites for their Phase II trial of the LSALT peptide targeting acute kidney injury rel...
